Received Jun 11, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
Extra dose administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. Previously administered products included Shingrix (first dose received on 17-OCT-2022) and Shingrix (second dose received on 28-DEC-2022). On 12-FEB-2026, the patient received the 3rd dose of Shingrix. On 12-FEB-2026, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra dose administered). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 04-JUN-2026 The batch number was not provided upon follow-up with the reporter.